Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice

Ann Van Der Jeugd, Arnaldo Parra-Damas, Raquel Baeta-Corral, Carlos M. Soto-Faguás, Tariq Ahmed, Frank M. Laferla, Lydia Giménez-Llort, Rudi D'Hooge, Carlos A. Saura

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Accumulation of amyloid-β plaques and tau contribute to the pathogenesis of Alzheimer's disease (AD), but it is unclear whether targeting tau pathology by antioxidants independently of amyloid-β causes beneficial effects on memory and neuropsychiatric symptoms. Selenium, an essential antioxidant element reduced in the aging brain, prevents development of neuropathology in AD transgenic mice at early disease stages. The therapeutic potential of selenium for ameliorating or reversing neuropsychiatric and cognitive behavioral symptoms at late AD stages is largely unknown. Here, we evaluated the effects of chronic dietary sodium selenate supplementation for 4 months in female 3xTg-AD mice at 12-14 months of age. Chronic sodium selenate treatment efficiently reversed hippocampal-dependent learning and memory impairments, and behavior- and neuropsychiatric-like symptoms in old female 3xTg-AD mice. Selenium significantly decreased the number of aggregated tau-positive neurons and astrogliosis, without globally affecting amyloid plaques, in the hippocampus of 3xTg-AD mice. These results indicate that selenium treatment reverses AD-like memory and neuropsychiatric symptoms by a mechanism involving reduction of aggregated tau and/or reactive astrocytes but not amyloid pathology. These results suggest that sodium selenate could be part of a combined therapeutic approach for the treatment of memory and neuropsychiatric symptoms in advanced AD stages.

Original languageEnglish
Article number6431
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - 1 Dec 2018

Fingerprint

Selenium
Alzheimer Disease
Pathology
Selenic Acid
Amyloid Plaques
Amyloid
Antioxidants
Dietary Sodium
Behavioral Symptoms
Neurobehavioral Manifestations
Astrocytes
Transgenic Mice
Hippocampus
Learning
Neurons
Brain
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Van Der Jeugd, A., Parra-Damas, A., Baeta-Corral, R., Soto-Faguás, C. M., Ahmed, T., Laferla, F. M., ... Saura, C. A. (2018). Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice. Scientific Reports, 8(1), [6431]. https://doi.org/10.1038/s41598-018-24741-0

Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice. / Van Der Jeugd, Ann; Parra-Damas, Arnaldo; Baeta-Corral, Raquel; Soto-Faguás, Carlos M.; Ahmed, Tariq; Laferla, Frank M.; Giménez-Llort, Lydia; D'Hooge, Rudi; Saura, Carlos A.

In: Scientific Reports, Vol. 8, No. 1, 6431, 01.12.2018.

Research output: Contribution to journalArticle

Van Der Jeugd, A, Parra-Damas, A, Baeta-Corral, R, Soto-Faguás, CM, Ahmed, T, Laferla, FM, Giménez-Llort, L, D'Hooge, R & Saura, CA 2018, 'Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice', Scientific Reports, vol. 8, no. 1, 6431. https://doi.org/10.1038/s41598-018-24741-0
Van Der Jeugd, Ann ; Parra-Damas, Arnaldo ; Baeta-Corral, Raquel ; Soto-Faguás, Carlos M. ; Ahmed, Tariq ; Laferla, Frank M. ; Giménez-Llort, Lydia ; D'Hooge, Rudi ; Saura, Carlos A. / Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{58bf055c4af54d7c9d11bdec90a43b31,
title = "Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice",
abstract = "Accumulation of amyloid-β plaques and tau contribute to the pathogenesis of Alzheimer's disease (AD), but it is unclear whether targeting tau pathology by antioxidants independently of amyloid-β causes beneficial effects on memory and neuropsychiatric symptoms. Selenium, an essential antioxidant element reduced in the aging brain, prevents development of neuropathology in AD transgenic mice at early disease stages. The therapeutic potential of selenium for ameliorating or reversing neuropsychiatric and cognitive behavioral symptoms at late AD stages is largely unknown. Here, we evaluated the effects of chronic dietary sodium selenate supplementation for 4 months in female 3xTg-AD mice at 12-14 months of age. Chronic sodium selenate treatment efficiently reversed hippocampal-dependent learning and memory impairments, and behavior- and neuropsychiatric-like symptoms in old female 3xTg-AD mice. Selenium significantly decreased the number of aggregated tau-positive neurons and astrogliosis, without globally affecting amyloid plaques, in the hippocampus of 3xTg-AD mice. These results indicate that selenium treatment reverses AD-like memory and neuropsychiatric symptoms by a mechanism involving reduction of aggregated tau and/or reactive astrocytes but not amyloid pathology. These results suggest that sodium selenate could be part of a combined therapeutic approach for the treatment of memory and neuropsychiatric symptoms in advanced AD stages.",
author = "{Van Der Jeugd}, Ann and Arnaldo Parra-Damas and Raquel Baeta-Corral and Soto-Fagu{\'a}s, {Carlos M.} and Tariq Ahmed and Laferla, {Frank M.} and Lydia Gim{\'e}nez-Llort and Rudi D'Hooge and Saura, {Carlos A.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-24741-0",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice

AU - Van Der Jeugd, Ann

AU - Parra-Damas, Arnaldo

AU - Baeta-Corral, Raquel

AU - Soto-Faguás, Carlos M.

AU - Ahmed, Tariq

AU - Laferla, Frank M.

AU - Giménez-Llort, Lydia

AU - D'Hooge, Rudi

AU - Saura, Carlos A.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Accumulation of amyloid-β plaques and tau contribute to the pathogenesis of Alzheimer's disease (AD), but it is unclear whether targeting tau pathology by antioxidants independently of amyloid-β causes beneficial effects on memory and neuropsychiatric symptoms. Selenium, an essential antioxidant element reduced in the aging brain, prevents development of neuropathology in AD transgenic mice at early disease stages. The therapeutic potential of selenium for ameliorating or reversing neuropsychiatric and cognitive behavioral symptoms at late AD stages is largely unknown. Here, we evaluated the effects of chronic dietary sodium selenate supplementation for 4 months in female 3xTg-AD mice at 12-14 months of age. Chronic sodium selenate treatment efficiently reversed hippocampal-dependent learning and memory impairments, and behavior- and neuropsychiatric-like symptoms in old female 3xTg-AD mice. Selenium significantly decreased the number of aggregated tau-positive neurons and astrogliosis, without globally affecting amyloid plaques, in the hippocampus of 3xTg-AD mice. These results indicate that selenium treatment reverses AD-like memory and neuropsychiatric symptoms by a mechanism involving reduction of aggregated tau and/or reactive astrocytes but not amyloid pathology. These results suggest that sodium selenate could be part of a combined therapeutic approach for the treatment of memory and neuropsychiatric symptoms in advanced AD stages.

AB - Accumulation of amyloid-β plaques and tau contribute to the pathogenesis of Alzheimer's disease (AD), but it is unclear whether targeting tau pathology by antioxidants independently of amyloid-β causes beneficial effects on memory and neuropsychiatric symptoms. Selenium, an essential antioxidant element reduced in the aging brain, prevents development of neuropathology in AD transgenic mice at early disease stages. The therapeutic potential of selenium for ameliorating or reversing neuropsychiatric and cognitive behavioral symptoms at late AD stages is largely unknown. Here, we evaluated the effects of chronic dietary sodium selenate supplementation for 4 months in female 3xTg-AD mice at 12-14 months of age. Chronic sodium selenate treatment efficiently reversed hippocampal-dependent learning and memory impairments, and behavior- and neuropsychiatric-like symptoms in old female 3xTg-AD mice. Selenium significantly decreased the number of aggregated tau-positive neurons and astrogliosis, without globally affecting amyloid plaques, in the hippocampus of 3xTg-AD mice. These results indicate that selenium treatment reverses AD-like memory and neuropsychiatric symptoms by a mechanism involving reduction of aggregated tau and/or reactive astrocytes but not amyloid pathology. These results suggest that sodium selenate could be part of a combined therapeutic approach for the treatment of memory and neuropsychiatric symptoms in advanced AD stages.

UR - http://www.scopus.com/inward/record.url?scp=85045991105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045991105&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-24741-0

DO - 10.1038/s41598-018-24741-0

M3 - Article

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 6431

ER -